XML 29 R17.htm IDEA: XBRL DOCUMENT v3.25.3
Segment and Geographic Data
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information SEGMENT INFORMATION
We segregate our operations into two reportable business
segments: (i) MedSurg and Neurotechnology and (ii)
Orthopaedics which aligns to our internal reporting structure and
how our Chief Operating Decision Maker (CODM) assesses the
performance of and allocates resources. The CODM is the Chief
Executive Officer. The CODM makes decisions on resource
allocation, assesses performance of the business, and monitors
budget versus actual results using segment operating income.
Our reportable segments and related disclosures reflect certain
reclassifications of prior year amounts from our Orthopaedics
segment to our MedSurg and Neurotechnology segment due to
changes in our internal reporting structure.
Segment Results
Three Months
Nine Months
2025
2024
2025
2024
MedSurg and Neurotechnology
$3,803
$3,324
$11,085
$9,636
Orthopaedics
2,254
2,170
6,860
6,523
Net sales
$6,057
$5,494
$17,945
$16,159
MedSurg and Neurotechnology
$1,426
$1,313
$4,162
$3,838
Orthopaedics
620
561
1,848
1,728
Cost of sales
$2,046
$1,874
$6,010
$5,566
MedSurg and Neurotechnology
$247
$205
$718
$594
Orthopaedics
132
136
399
406
Segment research, development and
engineering expenses
$379
$341
$1,117
$1,000
MedSurg and Neurotechnology
$972
$780
$2,893
$2,318
Orthopaedics
742
760
2,332
2,267
Segment selling, general and
administrative expenses
$1,714
$1,540
$5,225
$4,585
MedSurg and Neurotechnology
$56
$60
$171
$170
Orthopaedics
111
112
313
325
Segment depreciation and
amortization
$167
$172
$484
$495
Corporate and Other
$48
$40
$127
$118
Amortization of intangible assets
189
159
543
467
Total depreciation and amortization
$404
$371
$1,154
$1,080
MedSurg and Neurotechnology
$1,102
$966
$3,141
$2,716
Orthopaedics
649
601
1,968
1,797
Segment operating income
$1,751
$1,567
$5,109
$4,513
Items not allocated to segments:
Corporate and Other
$(202)
$(211)
$(670)
$(676)
Inventory stepped up to fair value
(61)
(29)
(160)
(38)
Acquisition and integration-related
charges
(39)
(48)
(302)
(49)
Amortization of intangible assets
(189)
(159)
(543)
(467)
Structural optimization and other special
charges
(41)
(22)
(93)
(92)
Goodwill and other impairments
(73)
(2)
(163)
(21)
Medical device regulation
(11)
(13)
(30)
(41)
Recall-related matters
(1)
—
(56)
(22)
Regulatory and legal matters
—
1
(7)
1
Consolidated operating income
$1,134
$1,084
$3,085
$3,108
Segment Assets
September 30
December 31
2025
2024
Assets:
MedSurg and Neurotechnology
$27,280
$23,115
Orthopaedics
18,192
18,507
Total segment assets
$45,472
$41,622
Corporate and Other
1,585
1,349
Total assets
$47,057
$42,971